1	Title
2	Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among
3	healthcare personnel in Pakistan: a test-negative, case-control study.
4	Authors:
5	Unab I. Khan MBBS, MS.
6	Associate Professor, Department of Family Medicine
7	Aga Khan University
8	PO BOX 3500, Stadium Road campus
9	Karachi, Pakistan
10	
11	Imran Hassan, MBBS.
12	Senior Instructor, Department of Family Medicine
13	Aga Khan University
14	PO Box 3500, Stadium Road campus
15	Karachi, Pakistan
16	
17	Mahnoor Niaz, MBBS.

18	Research Associate, Dean's Clinical Research Fellowship Program
19	Aga Khan University
20	PO BOX 3500, Stadium Road campus
21	Karachi, Pakistan
22	
23	Syed Iqbal Azam, MSc.
24	Assistant Professor, Department of Community Health Sciences
25	Aga Khan University
26	PO Box 3500, Stadium Road campus
27	Karachi 74800, Pakistan
28	
29	Zahra Hasan, PhD.
30	Professor, Department of Pathology
31	Aga Khan University
32	PO Box 3500, Stadium Road campus
33	Karachi 74800, Pakistan
34	

35	Syed Faisal Mahmood, MBBS.
36	Associate Professor, Section of Infectious Diseases
37	Department of Medicine
38	Aga Khan University
39	PO Box 3500, Stadium Road campus
40	Karachi 74800, Pakistan
41	
42	Asad Ali MBBS, MPH
43	Professor, Department of Pediatrics and Child Health
44	Aga Khan University
45	PO Box 3500, Stadium Road campus
46	Karachi 74800, Pakistan
47	
48	Corresponding Author:
49	Unab I. Khan MBBS, MS.
50	Associate Professor, Department of Family Medicine
51	Aga Khan University

52 PO Box 3500, Stadium Road campus 53 Karachi 74800, Pakistan Tel: +92 3486 4842 54 55 Email: unab.khan@aku.edu Word Count: 2979 56 57 **Abstract Objective** During the COVID-19 pandemic, several vaccines that were efficacious in 58 59 randomized controlled trials (RCTs) were authorized for mass vaccination. In developing countries, inactivated vaccines were widely administered. While inactivated vaccines 60 61 have been deemed effective in reducing disease severity, for healthcare personnel 62 (HCPs), effectiveness against COVID-19 infections is also essential to reduce the risk to 63 vulnerable patients and ensure a stable healthcare workforce. In addition, there are 64 limited studies examining inactivated vaccines' effectiveness against emerging SARS-CoV-2 variants in real-world settings. We aimed to estimate the effectiveness of 65 inactivated vaccines (BBIBP-CorV and CoronaVac) against RT-PCR-confirmed COVID-66 67 19 infections among HCPs in the setting of emerging SARS-CoV-2 variants in Pakistan. **Design, setting and participants** A retrospective matched test-negative case-control 68 analysis of existing data of HCPs at a private healthcare system in Pakistan. 69 70 **Methods** HCPs tested between April 1 and September 30, 2021, were included. Each 71 case was matched to two to six controls by the date of the RT-PCR test (\pm 7 days) to

72 reduce bias. We compared demographics, reasons for testing, and vaccination status 73 between cases and controls using chi-square for categorical variables and t-test for 74 continuous-level data. The odds of getting a PCR-confirmed SARS-COV-2 infection were calculated using conditional logistic regression, after adjusting for age, gender, and 75 76 work area. Vaccine effectiveness (VE) was calculated as percent VE using (1-OR)*100. 77 **Results** Inactivated vaccines were ineffective against COVID-19 infections ≥ 14 days after receiving the first dose [VE: 20% (95% CI: -10, 41; p=0.162)]. The vaccines 78 79 showed modest effectiveness ≥ 14 days after the second dose against COVID-19 infections [VE: 33% (95% CI: 11, 50; p=0.006)], and symptomatic COVID-19 infections 80 81 [VE: 36% (95% CI: 10, 54; p=0.009)]. 82 **Conclusions** Inactivated vaccines show modest effectiveness against COVID-19 infections in the setting of emerging VOCs. This builds a strong case for boosters and/or 83

84

additional vaccination.

Key Words COVID-19; epidemiology; immunology; infection control.

INTRODUCTION

86

The coronavirus disease 2019 (COVID-19) pandemic impacted global health, and as of 87 88 December 9, 2022, more than 657 million COVID-19 cases and six million deaths have 89 been reported to the WHO (1). Mass vaccination remains a cornerstone of public health interventions to counter the COVID-19 pandemic. Several vaccines have proven 90 91 efficacious in phase III trials and received emergency approval for mass vaccination 92 campaigns (2-4). As healthcare personnel (HCPs) are at a higher risk of contracting the 93 disease and can become a source of infection to vulnerable patients (5, 6), both Centers for Disease Control (CDC) and WHO (World Health Organization) have recommended 94 95 that national vaccine strategies prioritize vaccination of HCPs (7, 8). In Pakistan, the Government-driven vaccination campaign commenced in February 2021. 96 97 Vaccines with more than 50% efficacy in clinical trials were approved for mass 98 vaccination by the health regulatory authorities, and HCPs were prioritized for 99 vaccination (9). In the first phase, conventional inactivated vaccines BBIBP-CorV and 100 CoronaVac were administered. Over the next few months, replication-deficient 101 adenovector vaccines, including single-dose Ad5-nCoV (CanSino Bio) and the two-dose 102 ChAdOx1 nCoV-19 (Oxford-AstraZeneca), became available and were administered to 103 HCPs and the public (10). 104 While CoronaVac and BIBP-CorV were efficacious in clinical trials (11, 12) most were 105 conducted before SARS-CoV-2 variants of concern (VOCs) appeared. It, therefore, became crucial to assess the effectiveness of these vaccines in real-world settings during 106

the emergence of VOCs. This information can provide critical insights to help with policy decisions, including the need to give boosters or additional vaccination. We report the effectiveness of BBIBP-CorV and CoronaVac vaccines against RT-PCR-confirmed COVID-19 infections among HCPs, four months into the vaccination drive at a large private healthcare system in Pakistan, with an existing robust employee surveillance system. Our study was conducted in the setting of the third and fourth waves of COVID-19 in Pakistan during which the alpha, beta, gamma, and delta variants were prevalent (13, 14).

METHODS

Study Design

We conducted a matched, test-negative case-control study to evaluate the effectiveness of inactivated vaccines (BBIBP-CorV and CoronaVac) in reducing the odds of RT-PCR-confirmed COVID-19 infections in HCPs. Due to the rapidly changing vaccine uptake and prevalence of the disease in the community, we used the test-negative case-control design as recommended by the WHO (15). Our study population included all HCPs working at AKU who were tested for SARS-CoV-2 by RT-PCR at the AKU Hospital Clinical Laboratories between April 1 and September 30, 2021.

De-identified data was transferred from the Employee Health database to STATA v.15.0 for analysis. This study was approved by the Ethical Review Committee (ERC#: 2021-5629-18170), AKU.

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

Study Population Inclusion Criteria HCPs working at AKU and who got an RT-PCR test for SARS-CoV-2 at AKU Hospital Clinical Laboratories between April 1 and September 30, 2021, AND HCPs who were unvaccinated or vaccinated with one or two doses of BBIBP-CorV or CoronaVac. Exclusion Criteria HCPs with missing vaccination data. HCPs who received other vaccines (Ad5-nCoV, AZD1222 (ChAdOx1), mRNA-1273, Janssen (Johnson & Johnson), Gam-COVID-Vac, BNT162b2). HCPs who were enrolled in COVID-19 vaccine trials. **Study Setting** The Aga Khan University (AKU), a not-for-profit organization, runs a large healthcare system within Pakistan. Its main campus in Karachi is a 750-bed tertiary care hospital, a medical college, and a nursing school. Additionally, four secondary-care hospitals in two cities, 19 integrated medical centers, and 290 laboratory collection centers in 120 cities across Pakistan are part of the AKU healthcare system. The University employs 13960 staff, of which 80% are involved in direct health care (16).

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Since the beginning of the pandemic, multiple policies were put in place to facilitate HCPs getting tested. Free assessments, testing, and treatment were offered through the Office of Employee Health in the Department of Family Medicine. In addition, time away from work due to quarantine and isolation was not counted from HCPs' annual leaves. For each employee who tested positive, detailed contact tracing was performed. With these employee-friendly policies, HCPs have utilized the Office of Employee Health; to date, 30,000 tests have been conducted. HCPs were tested if: 1) they had symptoms consistent with COVID-19; 2) had a high-risk exposure, as defined by the CDC criteria (17), to a person infected with COVID-19 either in the community or at the workplace; or 3) were part of an outbreak investigation in a specific part of the University. All testing was performed by SARS-CoV-2 polymerase chain reaction on a nasal specimen using the Cobas® 6800 Roche assay (18). The samples were collected at the HCPs' workplace, and all testing was done at the AKU Hospital Clinical Laboratories, accredited by the College of American Pathologists, USA (16).Office of Employee Health maintained a password-protected database for COVID-19related data that is separate from HCPs' medical records. Once vaccination began, HCPs also provided dates of vaccine administration and the type of vaccine. Vaccine information was confirmed by verifying with the national database using the SMS-based system developed by the Government of Pakistan (10). Vaccinations were available

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

without any priority policy to all AKU HCPs, regardless of age, comorbidities, area of work, previous SARS-CoV-2 infections, etc. **Definitions** Healthcare Personnel: All employees working within the healthcare system with the potential of direct and indirect exposure to patients or infectious material were considered HCPs (19). Case: HCPs who had a positive SARS-CoV-2 RT-PCR test during the study period and had an absence of a positive test result in the preceding 90-day period. Control: HCPs with a negative SARS-CoV-2 RT-PCR test result during the study period and the absence of a positive test result in the preceding 90-day and the subsequent 14day period. Vaccination Status: Using the WHO definition (20), we defined vaccination status at the time of testing as: Unvaccinated: If no dose of any vaccine was received. Single dose received: If only the first dose of BBIBP-CorV or CoronaVac vaccine was received. This group was further divided into two subgroups: a) 0–13 days since receiving the first dose; b) \geq 14 days since receiving the first dose of a twodose vaccine.

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

• Two doses received: If both doses of BBIBP-CorV or CoronaVac vaccine were received. This group was also further divided into two: a) 0–13 days since receiving the final dose; b) \geq 14 days since receiving the final dose. COVID-19 Infection: All HCPs who tested positive for SARS-CoV-2 by RT-PCR, regardless of the presence or absence of symptoms. Symptomatic COVID-19: All HCPs who tested positive for SARS-CoV-2 by RT-PCR and had one or more COVID-19-related symptoms in 0-10 days before the RT-PCR test for SARS-CoV-2. Work Area: HCPs not working in direct clinical care (e.g. laboratory personnel, housekeeping staff, food providers, and administrative staff) were classified as "nonclinical"; those providing direct clinical care in areas not designated for patients with COVID were classified as "clinical non-COVID"; whereas HCPs working in designated areas for COVID-suspect or COVID-confirmed patients were categorized as "clinical COVID." Statistical analysis Data on demographics, results of the SARS-CoV2 RT-PCR test, vaccination status and dates, reason for testing, work area, and previous RT-PCR tests (within the preceding 90day period) were retrieved from the Office of Employee Health's database for statistical analysis. Vaccination status was allocated based on pre-defined definitions stated above.

As the study was during the surge, with percent positivity changing weekly, we matched cases and controls by the date of the RT-PCR test (\pm 7 days) to reduce bias. Each case was matched to a minimum of two and a maximum of six controls. We compared demographics, reason for testing, work area and vaccination status between cases and controls using chi-square for categorical variables and t-test for normally distributed continuous-level data. Using unvaccinated individuals as a reference, we used conditional logistic regression to estimate the odds of having RT-PCR-confirmed COVID-19 infections in HCPs vaccinated with a single dose and both doses of the two-dose inactivated vaccines. We calculated unadjusted and adjusted odds ratios, accounting for covariates that included age, sex (using females as a reference), and work area (using non-clinical as a reference). Vaccine effectiveness was calculated as Percent VE using (1- OR)*100. Additionally, we performed a subgroup analysis to assess the effectiveness of vaccines against symptomatic COVID-19 infection. Based on Hitchings et al study (21), we plotted the weekly positivity rate and cumulative vaccine coverage from the time vaccines were introduced (January 2021) to the end of the study period (end of delta surge in September 2021) to understand the impact of vaccines on COVID-19 infections in the healthcare system.

Patient and public involvement

220 Patient and the public were not involved in the conduct of this study.

RESULTS

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

Between April 1 and September 30, 2021, 4599 HCPs were tested for SARS-COV-2 via RT-PCR. Figure 1 shows the process for the selection of HCPs in analysis. After exclusion, 4074 HCPs remained, of whom 1037 tested positive and were classified as cases, and 3037 tested negative and were classified as controls. Of these, 3095 (959 cases and 2136 controls) were tested for symptoms. Cases were matched to controls by the date of the RT-PCR test (± 7 days). Each case was matched to two to six controls. No HCPs had to be excluded due to non-matching. Table 1 shows the characteristics of all cases and controls. Compared to controls, cases were older (35.3 \pm 9.7 vs. 33.1 \pm 8.6; p-value < 0.001). 73.9% of cases and 74.8% of controls were administered the BBIBP-CorV vaccine. 61.4% of cases and 60.3% of controls had received the second dose at least 14 days before the test. Among HCPs that had received both doses of vaccine before the RT-PCR test, there was no significant difference in mean duration between the second dose and test between cases and controls $(94.8 \pm 41.6 \text{ vs. } 91.7 \pm 45.1 \text{ days; p value} = 0.123).$

Table 1

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

Characteristics of all cases and controls (N=4074)

Characteristics	Cases 1037 (25%)	Controls 3037 (75%)	P-value
Age, years (mean \pm SD)	35.3 ± 9.7	33.1 ± 8.6	< 0.001
Age groups, n (%)			
19-29 years	363 (35.0)	1308 (43.1)	
30-39 years	378 (36.5)	1132 (37.3)	
40-49 years	184 (17.7)	411 (13.5)	

T		
96 (9.3)	162 (5.3)	
16 (1.5)	24 (0.8)	
512 (49.4)	1616 (53.2)	0.03
525 (50.6)	1421 (46.8)	
307 (29.6)	956 (31.5)	0.001
673 (64.9)	1813 (59.7)	
57 (5.5)	268 (8.8)	
6 (0.6)	130 (4.3)	
72 (6.9)	771 (25.4)	< 0.001
959 (92.5)	2136 (70.4)	
102 (9.8)	314 (10.3)	
18 (1.7)	58 (1.9)	
264 (25.5)	762 (25.1)	0.532
16 (1.5)	73 (2.4)	
637 (61.4)	1830 (60.3)	
102 (9.8)	314 (10.3)	
		0.534
	450 (14.8)	
113.5 ± 49.5	114.8 ± 53.9	0.498
94.8 ± 41.6	91.7 ± 45.1	0.123
	16 (1.5) 512 (49.4) 525 (50.6) 307 (29.6) 673 (64.9) 57 (5.5) 6 (0.6) 72 (6.9) 959 (92.5) 102 (9.8) 18 (1.7) 264 (25.5) 16 (1.5) 637 (61.4) 102 (9.8) 766 (73.9) 168 (16.2) 113.5 ± 49.5	16 (1.5) 24 (0.8) 512 (49.4) 1616 (53.2) 525 (50.6) 1421 (46.8) 307 (29.6) 956 (31.5) 673 (64.9) 1813 (59.7) 57 (5.5) 268 (8.8) 6 (0.6) 130 (4.3) 72 (6.9) 771 (25.4) 959 (92.5) 2136 (70.4) 102 (9.8) 314 (10.3) 18 (1.7) 58 (1.9) 264 (25.5) 762 (25.1) 16 (1.5) 73 (2.4) 637 (61.4) 1830 (60.3) 102 (9.8) 314 (10.3) 766 (73.9) 2271 (74.8) 168 (16.2) 450 (14.8) 113.5 ± 49.5 114.8 ± 53.9

SD: standard deviation; RT-PCR: reverse transcription polymerase chain reaction; HCP: health

care personnel; IQR: interquartile range

Table S1 describes the characteristics of symptomatic cases and controls (3095/4074

(76.0%). There was no significant difference in the mean interval between the onset of

symptoms and the RT-PCR test between cases and controls (2.1 \pm 2.0 vs. 1.9 \pm 2.3 days;

243 p=0.017).

239

240

241

Table 2 shows the odds of contracting COVID-19 infection by the time since vaccination. After adjusting for age, sex, and work area, we found that a single dose of the two-dose vaccines was ineffective within the first 13 days [VE: 30% (95% CI: -26, 62; p=0.234)] or even after 13 days had elapsed [VE: 20% (95% CI: -10, 41; p=0.162)]. This shows that one dose is not enough to prevent COVID-19 infections. While the vaccines were effective during the period < 14 days after the second dose [VE: 44% (95% CI: -2, 69; p=0.055)], the results were not significant. The vaccines were most effective \geq 14 days after the second dose against a COVID-19 infection [VE: 33% (95% CI: 11, 50; p=0.006)].

Table 2

Effectiveness of inactivated vaccines against all COVID-19 infections (symptomatic

and asymptomatic) (matched case-control)

	Unadjusted analysis		Adjusted analysis*		
	Odds ratio	P	Odds ratio (95%	Vaccine	P value
	(95% CI)	value	CI)	effectiveness**, % (95% CI)	
Model		0.098			< 0.001
Unvaccinated	1		1		
Single dose, <	0.76 (0.42,	0.354	0.70 (0.38, 1.26)	30 (-26, 62)	0.234
14 days	1.37)				
Single dose, ≥	0.83 (0.6, 1.12)	0.223	0.80 (0.59, 1.1)	20 (-10, 41)	0.162
14 days					
Two doses, <	0.58 (0.32,	0.069	0.56 (0.31, 1.02)	44 (-2, 69)	0.055
14 days	1.04)				
Two doses, ≥	0.72 (0.54,	0.024	0.66 (0.50, 0.89)	33 (11, 50)	0.006
14 days	0.96)				

^{*:} adjusted for age, sex, work area.

**: Vaccine Effectiveness= (1-aOR)*100

Table 3 shows the odds of contracting symptomatic COVID-19 infection by the time since vaccination. After adjusting for age, sex, and work area, we found that the first dose was ineffective against a symptomatic COVID-19 infection. The vaccines were most effective ≥ 14 days after the second dose against a symptomatic COVID-19 infection [VE: 36% (95% CI: 10, 54; p=0.009)].

Table 3

257

258

259

260

261

262

263

264

265

266

268

269

Effectiveness of inactivated vaccines against symptomatic COVID-19 infections

(matched case-control)

	Unadjusted analysis		Adjusted analysis*		
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	Vaccine effectiveness**, % (95% CI)	P value
Model		0.208			< 0.001
Unvaccinated	1		1		
Single dose, < 14 days	0.82 (0.42, 1.57)	0.546	0.71 (0.36, 1.38)	29 (-38, 64)	0.295
Single dose, ≥ 14 days	0.76 (0.53, 1.08)	0.125	0.75 (0.52, 1.07)	25 (-7, 48)	0.101
Two doses, < 14 days	0.60 (0.31. 1.15)	0.122	0.60 (0.31, 1.16)	40 (-16, 69)	0.131
Two doses, ≥ 14 days	0.69 (0.5, 0.96)	0.027	0.64 (0.46, 0.90)	36 (10, 54)	0.009

^{*:} adjusted for age, sex, work area.

**: Vaccine Effectiveness= (1-aOR)*100

Figure 2 displays the weekly RT-PCR tests conducted and the cumulative coverage of the first and second dose of inactivated vaccines among HCPs at our institution. We see that

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

healthcare workers in Turkey (65%) (25).

despite 75% coverage with 2-doses of inactivated vaccines, we observed an increase in positivity rates that correlated with the delta surge in Pakistan. This also shows the modest effectiveness of inactivated vaccines against VOCs. **DISCUSSION** Our study among HCPs found that BBIBP-CorV and CoronaVac were not as effective as seen in the efficacy trials (11, 12) in preventing COVID-19 infections, even 14 days after the second dose of the two-dose vaccines. Vaccines did not provide significant protection against infection after the first dose and within the first two weeks of the second dose. During our study period, the predominant variants in Pakistan switched from alpha, beta and gamma in April to June (13, 14) to the highly transmissible delta constituting up to 99% of the total genomes sequenced from July to September 2021 (22). Existing evidence on the effectiveness of inactivated vaccines against infections is inconsistent. Our results agree with a test-negative case-control study conducted in Brazil among healthcare workers during the gamma variant epidemic, which reported modest effectiveness of two doses of CoronaVac, with adjusted effectiveness of 37.1% against symptomatic COVID-19 infections and 37.9% against all COVID-19 infections (21). Similarly, moderate effectiveness against COVID-19 infections was estimated for inactivated vaccines during the delta variant epidemic in China (23, 24). In contrast, the effectiveness estimated in our study is lower than that of CoronaVac reported among

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

Several possibilities exist for the lower-than-expected effectiveness of inactivated vaccines in our study. Neutralizing antibody levels correlate with protection against COVID-19 infections (26, 27), and inactivated vaccines produce inferior antibody responses compared to mRNA vaccines (9, 28-30). Moreover, the weakened neutralization potency of inactivated vaccines against the dominant VOCs circulating during our study period, especially the vaccine-resistant delta variant, may have contributed to the limited effectiveness (30, 31). Indeed, studies conducted during the delta variant epidemic have demonstrated only modest effectiveness of two doses of BBIBP-CorV and CoronaVac against infections (23, 32). The mean interval between the second dose of vaccine and COVID-19 infection was more than 90 days in our study. Studies have demonstrated a decline in neutralizing antibody titers three months after vaccinations with the two-dose BBIBP-CorV and Corona Vac (30, 33, 34). It is possible that there was a significant waning of neutralizing antibody responses in our study population. Considering that inactivated vaccines were the most widely used vaccines in low-middle-income countries (LMICs), this finding supports the provision of homologous or heterologous booster doses among recipients of these vaccines. Our study has limitations. Our sample size did not allow us to match more than one variable. However, we did adjust for age, sex, and work area in the logistic model. Additionally, most HCPs in our setting did not get the severe disease or require hospitalization during the study period. Therefore, we cannot comment on vaccines'

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

effectiveness against severe disease. It is, however, essential to note that in healthcare settings, infected HCPs can risk spreading the infection to vulnerable patients. Thus, it is vital to examine not only from the perspective of the infected person but its impact on the system at large. As samples from HCPs in our study population did not undergo genomic sequencing, we could not directly ascertain effectiveness against the circulating VOCs. Finally, our study was conducted on HCPs and the results may not be generalizable to the population outside of healthcare settings. Despite these limitations, our study has clear strengths. Our findings are from a large, well-defined group of HCPs with consistent testing parameters that did not change during the study period. We used RT-PCR which is sensitive to detecting SARS-CoV-2 infections (18). Moreover, the vaccine status was highly accurate as it was validated through the national vaccine registry. Using a test-negative design, we mitigated the risk of bias/confounding associated with healthcare access and seeking behavior. Finally, our study was conducted among HCPs whose well-being is imperative to continue to offer uninterrupted, quality care to patients in a pandemic. Our study was conducted in an LMIC with a high population density and limited resources. Thus, examining the effectiveness of vaccines in these settings is essential to prevent public health crises. Pakistan and other developing economies with weak healthcare systems need effective vaccines to meet the unprecedented challenge of dealing with the morbidity and mortality associated with COVID-19. Our study adds new estimates to the effectiveness of these vaccines in HCPs. It may guide future policies in

Pakistan and other LMICs that mainly administered inactivated vaccines in their mass vaccination campaigns. By finding complete vaccination with CoronaVac and BBIBP-CorV vaccines to be only modestly effective against COVID-19 infections, our study strengthens the case for boosters or additional vaccination among recipients of these vaccines. Additionally, with new variants being identified regularly, it is crucial to prioritize conducting studies at different times and in various settings to continuously examine the effectiveness of these vaccines and boosters against the prevailing variants in real-world settings.

CONCLUSIONS

Absence of strong effectiveness of inactivated vaccines against COVID-19 infections among HCPs, especially during the spread of VOCs in our setting is concerning and builds a case for boosters and/or additional vaccination. There is a need for further studies to continuously assess effectiveness in the setting of emerging variants to guide policies regarding boosters to ensure adequate protectiveness.

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

Author Contributions: Conception and design: UIK, IH, AA Analysis and Interpretation: UIK, IH, IA, MN Drafting and Revising manuscript: MN, ZH, SFM, AA, IH, UIK Final approval of manuscript: UIK **Acknowledgments** We acknowledge the support of Professor Adil Haider, Dean AKU-Medical College and Professor Shahid Shafi, previous CEO of Aga Khan University Hospital, Pakistan. In addition, we thank the Employee Health team Shehreen Somani RN, Sania Nawaz RN, Noorjehan Momin RN, Dr. Asif Hakim, and the entire Family Medicine team for providing care to employees. **Ethics Statements** Participants consent to participate Deidentified data was used for analysis and consent was not required. **Ethics Approval** This study was approved by the Ethical Review Committee (ERC#: 2021-5629-18170), Aga Khan University. **Competing interests** All authors declare no conflicts of interest, support or financial relationship with any organization or other activities with any influence on the submitted work.

As this is employee-related data, we do not have permission to make it publicly accessible. However, data are available from the corresponding author after approval from the University's ethics review committee on reasonable request.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

References

- 374 1. WHO Coronavirus (COVID-19) Dashboard: World Health Organization; cited January 9,
- 375 2023 [Available from: https://covid19.who.int/.
- Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety
- and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
- analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet.
- 379 2021;397(10269):99-111.
- 380 3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
- 381 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
- 382 4. Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and Safety of COVID-19
- Vaccines in Phase III Trials: A Meta-Analysis. Vaccines (Basel). 2021;9(6).
- 384 5. Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, et al. Risk assessment
- and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-
- 386 COVID-19 hospitals in Southern Switzerland. The Lancet Regional Health Europe.
- 387 2021;1:100013.
- Witrat V, Maillard A, Raybaud A, Wackenheim C, Chanzy B, Nguyen S, et al. Effect of
- Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection
- 390 among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study. Vaccines
- 391 (Basel). 2021;9(8).
- 392 7. Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, et al. The
- 393 Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial
- 394 Supplies of COVID-19 Vaccine United States, 2020. MMWR Morb Mortal Wkly Rep.
- 395 2020;69(49):1857-9.
- 396 8. World Health O. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in
- 397 the context of limited supply: an approach to inform planning and subsequent recommendations
- based on epidemiological setting and vaccine supply scenarios, first issued 20 October 2020,
- latest update 16 July 2021. Geneva: World Health Organization; 2021 2021. Contract No.:
- 400 WHO/2019-nCoV/Vaccines/SAGE/Prioritization/2021.1.
- 401 9. Algassieh R, Suleiman A, Abu-Halaweh S, Santarisi A, Shatnawi O, Shdaifat L, et al.
- 402 Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers.
- 403 Vaccines (Basel). 2021;9(11).
- 404 10. COVID-19 Health Advisory Platform by Ministry of National Health Services
- 405 Regulations & Coordinations GoP.
- 406 11. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2
- 407 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A
- 408 Randomized Clinical Trial. Jama. 2021;326(1):35-45.
- 409 12. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and
- safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a
- double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet.
- 412 2021;398(10296):213-22.
- 413 13. Nasir A, Aamir UB, Kanji A, Samreen A, Ansar Z, Ghanchi NK, et al. SARS-CoV-2
- Variants of Concern (VOC) Alpha, Beta, Gamma, Delta, and Omicron coincident with
- consecutive pandemic waves in Pakistan. medRxiv. 2022:2022.05.19.22275149.

- 416 14. Hasan Z, Aamir U, Nasir A, Kanji A, Samreen A, Bukhari A, et al. Changing SARS-
- 417 CoV-2 variants in Karachi, Pakistan from alpha to delta through COVID-19 waves three and
- 418 four2021.
- 419 15. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of
- limited supply: an approach to inform planning and subsequent recommendations based on
- 421 epidemiological setting and vaccine supply scenarios. who.int/publications: World Health
- Organization; 2021 [updated 21 January 2022; cited 2022 13 January 2022]. Available from:
- 423 <u>https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-</u>
- 424 vaccines.
- 425 16. AKUH Clinical Laboratory Re-Accredited by the College of American Pathologists for
- 426 the Third Time 2022 [Available from:
- 427 https://hospitals.aku.edu/pakistan/AboutUs/News/Pages/re-accreditation-of-akuh-laboratories-
- 428 <u>for-the-third-time.aspx</u>.
- 429 17. Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or
- 430 Exposure to SARS-CoV-2: Centers for Disease Control and Prevention; 2020 [updated 21 Jnuary
- 431 202213 January 2022]. Available from: https://www.cdc.gov/coronavirus/2019-
- 432 ncov/hcp/guidance-risk-assesment-hcp.html.
- 433 18. Roche receives FDA authorisation for testing of asymptomatic people with the cobas
- 434 SARS-CoV-2 Test to help control the spread of COVID-19 [press release]. 2021.
- 435 19. Kuhar DT, Carrico R, Cox K, de Perio MA. Infection Control in Healthcare Personnel.
- 436 Appendix 2: Terminology: U.S. Department of Health and Human Services; 2019 [updated
- 437 October 2, 2019.
- 438 20. Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation
- of post-introduction COVID-19 Vaccine Effectiveness: Summary of interim guidance of the
- World Health Organization. Vaccine. 2021.
- 441 21. Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al.
- 442 Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2
- Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg
- 444 Health Am. 2021;1:100025.
- 445 22. Umair M, Ikram A, Rehman Z, Haider SA, Ammar M, Badar N, et al. Genomic diversity
- of SARS-CoV-2 in Pakistan during the fourth wave of pandemic. J Med Virol.
- 447 2022;94(10):4869-77.
- 448 23. Wu D, Zhang Y, Tang L, Wang F, Ye Y, Ma C, et al. Effectiveness of Inactivated
- 449 COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta
- 450 Variant: Real World Study and Evidence China, 2021. China CDC Wkly. 2022;4(4):57-65.
- 451 24. Kang M, Yi Y, Li Y, Sun L, Deng A, Hu T, et al. Effectiveness of Inactivated COVID-19
- 452 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in
- 453 Guangdong, China: A Cohort Study. Ann Intern Med. 2022;175(4):533-40.
- 454 25. Copur B, Surme S, Sayili U, Tuncer G, Pehlivanoglu F, Sengoz G. Effectiveness of
- 455 CoronaVac vaccination against COVID-19 development in healthcare workers: real-life data.
- 456 Future Microbiology. 2022;17(17):1381-91.
- 457 26. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic
- 459 SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-11.

- 460 27. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al.
- Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine.
- 462 2021;39(32):4423-8.
- 463 28. Mok CKP, Cohen CA, Cheng SMS, Chen C, Kwok KO, Yiu K, et al. Comparison of the
- immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology.
- 465 2022;27(4):301-10.
- 466 29. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of
- 467 mRNA and inactivated vaccines against COVID-19. Lancet Microbe. 2021;2(9):e423.
- 468 30. Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, et al. Waning immune responses against
- 469 SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine.
- 470 2022;77:103904.
- 471 31. Yu X, Wei D, Xu W, Liu C, Guo W, Li X, et al. Neutralizing activity of BBIBP-CorV
- 472 vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nat
- 473 Commun. 2022;13(1):1788.
- 32. Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N,
- 475 Satdhabudha A, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens
- during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes
- 477 Infect. 2022;11(1):585-92.
- 478 33. Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Wijesinghe
- A, et al. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. Immun
- 480 Inflamm Dis. 2022;10(6):e621.
- 481 34. Suah JL, Husin M, Tok PSK, Tng BH, Thevananthan T, Low EV, et al. Waning COVID-
- 482 19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study.
- 483 Int J Infect Dis. 2022;119:69-76.

486 487 **Figure Legends:** 488 489 Figure 1 490 Process for the selection of HCPs. 491 *Other vaccines: Ad5-nCoV (n=342), AZD1222 (ChAdOx1) (n=60), mRNA-1273 (n=20), 492 Janssen (n=1), Gam-COVID-Vac (n=18), BNT162b2 (n=11). 493 494 Figure 2 495 Weekly number of RT-PCR tests conducted and cumulative coverage of inactivated vaccines 496 (BBIBP-CorV and CoronaVac) among HCPs at our institution from January 1-September 30, 497 2021. Negative and positive RT-PCR tests are represented as red and blue bars, respectively. 498 Cumulative coverage of first and second dose of inactivated vaccines is shown by the yellow and 499 green lines, respectively. Our study period, April 1-September 30, 2021, is highlighted in pink.



